Ironwood Pharmaceuticals Inc. (IRWD)
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024.
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q3 2024 Earnings Call Transcript November 7, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Operating Officer & Chief Financial Officer Conference Call Participants Amy Li - Jefferies David Amsellem - Piper Sandler Jason Butler - Citizens JMP Mohit Bansal - Wells Fargo Operator Thank you for standing by. My name is Louella, and I will be your conference operator today.
Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.
Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2024 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Operating Officer & Chief Financial Officer Andrew Davis - Chief Business Officer Conference Call Participants David Amsellem - Piper Sandler Amy Li - Jefferies Mohit Bansal - Wells Fargo Jason Butler - Citizens JMP Tim Chiang - Capital One Operator Thank you for standing by. My name, Celine, and I will be your conference operator today.
Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates
Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates.
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2
Ironwood Pharmaceuticals (IRWD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.17. This compares to earnings of $0.31 per share a year ago.
Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q2 Earnings Expected to Decline
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Schall Law Firm Starts Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Begin Conversation
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Initiates Inquiry Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Incurred Losses To Initiate Dialogue
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Suffered Losses To Initiate Contact
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Begins Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Establish Communication
LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors With Losses To Connect
LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
